Back to News
Market Impact: 0.15
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?
Source: zacks.com
Healthcare & BiotechAnalyst EstimatesMarket Technicals & Flows
Intellia Therapeutics (NTLA) shares rose in the last session on above-average trading volume, but recent earnings-estimate revisions do not indicate further upside strength. The article provides no share-price change or revision figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.00
Ticker Sentiment
NTLA-0.15
More News
- Cathie Wood’s ARK sells DraftKings stock and buys CRISPR Therapeutics
- Verizon stock heads for worst day since 2002 as SpaceX U.S. network plans whack telcos
- French yields are near levels not seen since 2002. Why that could give U.S. Treasurys a boost
- What's behind the recovery rally in tech stocks — plus, Elon Musk's very good week
- SpaceX’s Wireless Threat Rises With Spectrum Deal
- Pilot killed in attacks by Iran-backed Houthis on Riyadh airport; Saudi-led coalition vows 'firm' response
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Choosing an AI Copilot for Equity Research
- Weekly Update: Advanced Search Filters, Redesigned Ticker Dashboard, and Improved Search Experience